Practical synthesis of a vanilloid receptor-1 antagonist

Journal of Organic Chemistry

Volumn 73, Issue 9, 2008, Pages 3508-3515

  Thiel, Oliver R ^a   Bernard, Charles ^a   King, Tony ^a   Dilmeghani Seran, Mina ^a   Bostick, Tracy ^a   Larsen, Robert D ^a   Faul, Margaret M ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL APPLICATIONS; PATIENT TREATMENT; SYNTHESIS (CHEMICAL);

BENZOTHIAZOLE; ENANTIOPURE PIPERAZINE; PAIN TREATMENT AGENTS;

DRUG PRODUCTS;

BENZOTHIAZOLE; PIPERAZINE; PYRIMIDINE DERIVATIVE; VANILLOID RECEPTOR 1;

ARTICLE; CHEMICAL REACTION; MOLECULE; SYNTHESIS;

ACETAMIDES; BENZOTHIAZOLES; CATALYSIS; METALS; MOLECULAR STRUCTURE; PIPERAZINES; PYRIMIDINES; STEREOISOMERISM; THIADIAZOLES; TRPV CATION CHANNELS;

EID: 43449104720     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo8002216     Document Type: Article

References (43)

1. For a general overview see: (a) Szallasi, A.; Appendino, G. J. Med. Chem. 2004, 47, 2717.
2. (b) Rami, K. H.; Gunthorpe, M. J. Drug Discovery Today: Ther. Strategies 2004, 1, 97-104.
3. For disclosure of clinical development candidates see: (a) Lukin, K.; Hsu, M. C.; Chambournier, G.; Kotecki, B.; Venkatramani, C. J.; Leanna, M. R. Org. Process Res. Dev. 2007, 11, 578.
4. (b) Rami, H. K.; Thompson, M.; Stemp, G.; Fell, S.; Jerman, J. C.; Stevens, A. J.; Smart, D.; Sargent, B.; Sanderson, D.; Randall, A. D.; Gunthorpe, M. J.; Davis, J. B. Bioorg. Med. Chem. Lett. 2006, 16, 3287.
5. (a) Norman, M. H.; Fotsch, C.; Doherty, E. M.; Bo, Y.; Chen, N.; Chakrabarti, P.; Gavva, N. R.; Nishimura, N.; Nixey, T.; Ognyanov, V.; Rzasa, R.; Stec, M.; Surapaneni, S.; Tamir, R.; Viswanadhan, V.; Zhu, J.; Treanor, J. S. J. Med. Chem. 2007, 50, 3497.
6. (b) Doherty, E. M.; Bannon, A. W.; Bo, Y.; Chen, N.; Dominguez, C.; Falsey, J.; Fotsch, C.; Gavva, N. R.; Katon, J.; Nixey, T.; Ognyanov, V.; Pettus, L.; Rzasa, R.; Stec, M.; Surapaneni, S.; Tamir, R.; Zhu, J.; Treanor, J. S.; Norman, M. H. J. Med. Chem. 2007, 50, 3515.
7. (c) Wang, H.; Katon, J.; Balan, C.; Bannon, A. W.; Bernard, C.; Doherty, E. M.; Dominguez, C.; Gavva, N. R.; Gore, V.; Ma, V.; Nishimura, N.; Surapaneni, S.; Tang, P.; Tamir, R.; Thiel, O. R.; Treanor, J. S.; Norman, M. H. J. Med. Chem. 2007, 50, 3528.
8. $424 for 25 g.
9. (a) Erlenmeyer, H.; Ueberwasser, H. Helv. Chim. Acta 1942, 25, 515.
10. (b) Feng, P. K.; Fernando, Q. J. Am. Chem. Soc. 1960, 82, 2115.
11. (c) Gupta, R. R.; Ojha, K. G.; Kalwania, G. S.; Kumar, M. Heterocycles 1980, 14, 1145.
12. Zil'berman, E. N.; Lazaris, A. Y. J. Gen. Chem. USSR. 1963, 33, 1012.
13. (a) Hugerschoff, A. Chem. Ber. 1901, 34, 3130.
14. (b) Hugerschoff, A. Chem. Ber. 1903, 36, 3121.
15. Identified by LC/MS analysis.
16. The intermediates in this proposed mechanism were not observed directly.
17. (a) Mamaeva, E. A.; Bakibaev, A. A. Tetrahedron 2003, 59, 7521.
18. (b) Hector, D. S. Chem. Ber. 1889, 22, 1176.
19. (c) Butler, A. R.; Glidewell, C.; Liles, D. S. Acta Crystallogr., Sect. B 1978, 34, 3241.
20. Jordan, A. D.; Lou, C.; Reitz, A. B. J. Org. Chem. 2003, 68, 8693.
21. Une, T. J.; Sam, A. J. Am. Chem. Soc. 1961, 83, 2223.
22. The following conditions were used: acetic anhydride, triethylamine, ethyl acetate, rt.
23. An enantioselective hydroamination (for a leading reference see: Kawatsura, M.; Hartwig, J. F. J. Am. Chem. Soc. 2000, 122, 9546. of 4-fluorostyrene with piperazine also appears feasible, but this option was not explored due to the relatively high price of the starting material.
24. For examples on related substrates see: (a) Arink, A. M.; Kronenburg, C. M. P.; Jastrzebski, J. T. B. H.; Lutz, M.; Spek, A. W.; Gossage, R. A.; van Koten, G. J. Am. Chem. Soc. 2004, 126, 16249.
25. (b) Tagat, J. R.; Steensma, R. W.; McCombie, S. T. W.; Nazareno, D. V.; Lin, S.-I.; Neustadt, B. R.; Cox, K.; Xu, S.; Wojcik, L.; Murray, M. G.; Vantuno, N.; Baroudy, B. M.; Strizki, J. M. J. Med. Chem. 2001, 44, 3343.
26. The obtained result was slightly inferior to results reported in the literature but no detailed optimization of this reaction was carried out at this point. For a reference see: Mathre, D. J.; Thompson, A. S.; Douglas, A. W.; Hoogsten, K.; Carroll, J. D.; Gorley, E. Q.; Grabowski, E. J. J. J. Org. Chem. 1993, 58, 2880.
27. Barnett, C. J.; Huff, B.; Kobierski, M. E.; Letourneau, M.; Wilson, T. M. J. Org. Chem. 2004, 69, 7653.
28. Ault, A. Org. Synth. 1969, 49, 93.
29. Murahashi, S.-I.; Kondo, K.; Hakata, T. Tetrahedron Lett. 1982, 23, 229.
30. Abbenhuis, R. A.T.M.; Boersma, J.; van Koten, G. J. Org. Chem. 1998, 63, 4282.
31. Fujita, K.; Fujii, T.; Yamguchi, R. Org. Lett. 2004, 6, 3525.
32. A ruthenium-catalyzed synthesis of piperazines was reported earlier (Abbenhuis, R. A. T. M.; Boersma, J.; van Koten, G. J. Org. Chem. 1998, 63, 4282. ) but elevated temperatures of 180 °C were necessary. The successful examples (yields 7-34%) were limited to cyclization with anilines. No products were obtained when primary aliphatic amines were used in the reaction.
33. Pàmies, O.; Bäckvall, J. E. Chem. Eur. J. 2001, 7, 5052.
34. Shvo, Y.; Czarkie, D.; Rahamim, Y. J. Am. Chem. Soc. 1986, 108, 7400.
35. Choi, J. H.; Kim, Y. H.; Nam, S. H.; Shin, S. T.; Kim, M.-J.; Park, J. Angew. Chem., Int. Ed. 2002, 41, 2373.
36. (a) Opalka, C. J.; D'Ambra, T. E.; Facoone, J. J.; Bpdson, G.; Cossement, E. Synthesis 1995, 766.
37. (b) Pflum, D. A.; Krishnamurthy, D.; Zhengxu, H.; Senanayke, S. A. Tetrahedron Lett. 2002, 43, 923.
38. (c) Bazzicalupi, C.; Bencini, A.; Fust, V.; Micheloni, M.; Paoletti, P.; Valtancoli, B. J. Org. Chem. 1994, 59, 7508.
39. Ksander, G. M.; deJesus, R.; Yuan, A.; Fink, C.; Moskal, M.; Carlson, E.; Kukkola, P.; Bilci, N.; Wallace, E.; Neubert, A.; Feldman, D.; Mogelesky, T.; Poirier, K.; Jeune, M.; Steele, R.; Wasvery, J.; Stephan, Z.; Cahill, E.; Webb, R.; Navarette, A.; Lee, W.; Gibson, J.; Alexander, N.; Sharif, H.; Hospattankar, A. J. Med. Chem. 2001, 44, 4677.
40. Gold, E. H.; Babad, E. J. Org. Chem. 1972, 37, 2208.
41. Bird, I.; Shuker, D. E. G. J. Labeled Compd. Radiopharm. 1985, 22, 109.
42. The equimolar amounts for the starting materials are based on stoichiometry calculation not accounting for the potency of the starting materials. It was later discovered that the starting material 2 often only has potency (wt/wt %) of 90-95%, which then de facto leads to use of excess 4,6-dichloropyrimidine in the coupling reaction.
43. An additional suspension in ethanol/water, followed by filtration was needed to reduce the content of DMF in the API (∼4000 ppm in the crude material).